19:54 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on Aptose blood cancer candidate

Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) said FDA lifted a two-and-a-half year clinical hold on a Phase Ib trial evaluating IV APTO-253 in patients with hematologic malignancies. In 2015, FDA placed a hold on the open-label, dose-escalation,...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it received a response from FDA regarding a clinical hold the agency placed last November on its open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. According to Aptose,...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it submitted a formal response to FDA’s requests following a November 2015 clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The company had voluntarily...
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting the MAP4K3-KLF2/KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels and symptoms including headaches, seizures and hemorrhages....
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

FDA placed a clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The hold follows a voluntary suspension of dosing and preliminary review that found concerns regarding...
07:00 , Jul 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kruppel-like factor 4 (KLF4; EZF); galectin-3 (LGALS3)

Cardiovascular disease INDICATION: Atherosclerosis Cell culture and mouse studies suggest inhibiting KLF4 could help treat atherosclerosis. In atherosclerotic plaques, phenotypic conversion of smooth muscle cells to macrophage-like LGALS3-positive cells increases inflammation and reduces fibrous cap area, which...
07:00 , Jul 30, 2015 |  BC Innovations  |  Targets & Mechanisms

Muscling in on atherosclerosis

A finding from the University of Virginia overturning assumptions about the biology of atherosclerotic plaques could prompt companies to rethink their therapeutic strategies for the disease. Using a series of in vitro and in vivo...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Aptose Biosciences, Oregon Health & Science University, LLS cancer news

Aptose (formerly Lorus Therapeutics Inc.) joined the Beat AML cancer research initiative to create a profile of the possible genetic drivers of acute myelogenous leukemia (AML). Oregon's Knight Cancer Institute and Aptose will profile...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

LOR-253: Phase Ib start

In mid-September, Lorus will begin an open-label, U.S. Phase Ib trial to evaluate LOR-253 in about 45-60 patients with relapsed or refractory hematologic malignancies, including acute myelogenous leukemia (AML), high-risk myelodysplastic syndrome (MDS), lymphoma and...